
THE NOMINATION COMMITTEE OF CELLAVISION'S FULL PROPOSAL TO THE ANNUAL GENERAL MEETING 2026

The Nomination Committee, appointed in accordance with the principles decided at the Annual General Meeting 2024, consisted of the four largest shareholders represented by Nicklas Hansen, appointed by William Demant Invest A/S, Joel Eklund (Chairman of the Nomination Committee), appointed by Grenlunden CEVI AB, Erik Ståhl Hallengren, appointed by SEB Funds and Christer Fåhraeus, appointed by Christer Fåhraeus and company.

Election of Chairman of the AGM (item 2)

The Nomination Committee proposes that lawyer Anton Walfridsson at Fredersen law firm to be elected Chairman of the AGM.

Resolution on number of Board members, deputy directors, auditors and deputy auditors (item 12)

The Nomination Committee proposes that the number of Board members elected to be six (6). No deputy Board members are proposed. The Nomination Committee further proposes that the number of auditors should be one (1) with no deputy auditors.

Resolution on the remuneration to the Board of Directors and auditor (item 13)

The Nomination Committee proposes that the remuneration to the Chairman shall be paid with SEK 755,000 (previously SEK 755,000) and that remuneration to other members of the Board shall be paid with SEK 280,000 (previously SEK 280,000) each, but that no remuneration shall be paid to members of the Board who are permanently employed by the company; additional remuneration shall be paid by SEK 100,000 (previously SEK 100,000) to the Chairman of the Board's Audit Committee and by SEK 50,000 (previously SEK 50,000) to other members of the Board's Audit Committee, as well as SEK 50,000 (previously SEK 50,000) to the Chairman of the Board's Remuneration Committee and SEK 25,000 (previously SEK 25,000) to other members of the Board's Remuneration Committee.

The Nomination Committee further proposes that the remuneration to the auditor shall be paid in accordance with approved invoicing.

Election of Board members (item 14)

Until the end of the next Annual General Meeting, the Nomination Committee proposes re-election of the Board members Mikael Worning, Christer Fåhraeus, Stefan Wolf, Ann-Charlotte Jarleryd and Emil Hjalmarsson, and that Zlatko Rihter is elected as new Board member. Louise Armstrong-Denby has declined re-election.

The Nomination Committee's motivated statement on the election of the Board, see Appendix 1.

Election of Chairman of the Board (item 15)

Zlatko Rihter is proposed to be elected as Chairman of the Board. Mikael Worning has declined re-election as Chairman of the Board, but is available to serve as a Board member.

Election of auditor (item 16)

In accordance with the Board's recommendation, the Nomination Committee proposes election the registered auditing firm KPMG AB until the end of the 2027 Annual General Meeting. KPMG AB has announced that the authorized auditor Jonas Nihlberg will be the principal auditor in the event KPMG AB is appointed as auditor.

Decision on principles for the appointment of the Nomination Committee (item 17)

It is proposed that the Annual General Meeting adopt principles for the appointment of the Nomination Committee to apply for the time being in accordance with Appendix 2.

Appendix 1

THE NOMINATION COMMITTEE'S MOTIVATED STATEMENT

The Nomination Committee of CellaVision AB (publ) motivates its proposal to the Board of Directors as follows. In accordance with Rule 4.1 Swedish Corporate Governance Code, the Board's composition shall be appropriate to fit the company's operations, phase of development and other relevant circumstances. The Board members elected by the Annual General Meeting should collectively exhibit diversity and breadth of qualifications, experience, and background. An even gender distribution should be sought. As a diversity policy, the Nomination Committee has applied Rule 4.1 of the Swedish Corporate Governance Code when drafting its proposal.

The Nomination Committee considers that the Board is well functioning with a broad and strong base of experience, characterized by versatility and breadth. The Nomination Committee's ambition is a Board composition at CellaVision with broad experience from both international companies and in the specialist area of hematology and adjoining areas. Several members have experience in CellaVision's strategically important areas. The Board also has high level of competence of relevance to the company, both in terms of the company's operations and industry and in the special conditions under which listed companies operate. According to the Nomination Committee, the proposed Board composition provides an appropriate composition to meet the needs the Company's operations will require, considering the Company's operations, strategic orientation, and governance. The board is also of a suitable size. In its assessment, the Nomination Committee has taken into account that Louise Armstrong-Denby has declined re-election.

The Nomination Committee also makes the assessment that continuity of Board work is of great importance to CellaVision. It can be noted that the current composition of the Board has a somewhat uneven gender distribution. The Nomination Committee's proposal to the Annual General Meeting means that one of the Board's six members, corresponding to approximately 17 percent, are women. In light of this, the Nomination Committee notes that an equalization of the gender distribution on the Board must occur over time.

Further information on all proposed members can be found on the company's website www.cellavision.com.

Considering the above, the Nomination Committee has proposed the re-election of Mikael Worning, Christer Fåhraeus, Stefan Wolf, Ann-Charlotte Jarleryd and Emil Hjalmarsson, as well as the election of Zlatko Rihter. New election of Zlatko Rihter as Chairman of the Board is proposed.

To be able to assess whether the proposed Board members are to be considered independent in relation to CellaVision and its management and major shareholders in CellaVision, the Nomination Committee has gathered information about the proposed Board members. The Nomination Committee has thus assessed that none of the nominees are to be regarded as dependent on the company or its management. Emil Hjalmarsson is to be considered as dependent in relation to major shareholders in CellaVision AB.

Appendix 2

DECISION ON PRINCIPLES FOR APPOINTMENT OF NOMINATION COMMITTEE

The Chairman of the Board shall, as soon as the registered ownership conditions in the company as of 31 July the year before the Annual General Meeting are known, contact the four largest registered shareholders according to the company's share book and ask them to appoint one member each to the Nomination Committee. If such shareholders do not wish to appoint a member, the next largest registered shareholders will be asked in the order of size until four shareholders' representatives have been appointed. Together, the four largest shareholders form the nomination committee, where the Chairman of the Board is convener and can participate as an adjunct but is not a member of the Nomination Committee. The names of the members of the Nomination Committee shall be published by the company no later than six months before the next Annual General Meeting. When establishing the

Nomination Committee, the rules on independence in the Swedish Corporate Governance Code (the "Code") must be taken into account.

The Nomination Committee shall follow and fulfill the tasks that follow from the Code and shall submit proposals for a process for the appointment of a new Nomination Committee to the next Annual General Meeting. If a shareholder who has appointed a member of the Nomination Committee, prior to the completion of the Nomination Committee's mandate,

receives a lower position on the list of the largest voting shareholders in the company, the member appointed by the shareholder, unless the Nomination Committee so decides, is replaced by a new member appointed by the shareholder, that at the point in time is the largest registered shareholder in terms of votes and who is not already represented in the Nomination Committee. Should any of the members of the Nomination Committee, before the Nomination Committee's assignment is completed, resign, or for any other reason, cease to represent the shareholder who has appointed the member, and if the appointing shareholder so requests, shall be replaced by a new member appointed by the shareholder.

The term of office of the Nomination Committee thus appointed shall run until a new nomination committee has taken office. No remuneration for the members' work in the Nomination Committee shall be paid. If necessary, the company must be able to bear reasonable costs that the Nomination Committee deems necessary for the Nomination Committee to be able to fulfill its task. The Nominating Committee may also appoint members to the Nominating Committee if deemed appropriate; however, an adjunct member should not have voting rights in the Nomination Committee.
